EVOLUTION AT MERCK - INVENTING FOR LIFE
LYNPARZA: SHOWING EFFICACY BEYOND
WOMEN'S CANCERS
•
1L, nonBRCA, KEYTRUDA combo (KEYLYNK-001)
•
1L Maintenance BRCA+ (SOLO-1) - Approved
•
•
•
•
1L Maintenance, All Comers Combo + Bev (PAOLA-1)
PSR, All Comers Combo + Cediranib (GY004)
PRR, All Comers Combo + Cediranib (GY005)
2L+ PSR (SOLO2/Study19) - Approved
3L+ PSR, gBRCA Treatment (SOLO3)
Breast
cancer
Ovarian
cancer
.
mBC, gBRCA (OlympiAD) - Approved
•
HER2- Adjuvant, gBRCAM (OlympiA)
mCRPC, All Comers (KEYLYNK-010)
•
mCRPC, HRRm (PROfound)
mCRPC, All Comers Combo + Abiraterone
(PROpel)
Pancreatic
cancer
1L Maintenance gBRCA
(POLO)
Prostate
cancer
Efficacy
•
Lung
cancer
1L NSQ NSCLC (KEYLYNK-006)
•
1L SQ NSCLC (KEYLYNK-008)
Median PFS for patients treated with olaparib
nearly doubled (7.4 months) compared to
patients treated with placebo (3.8 months)
*
47%*
reduction in risk of disease
progression or death,
compared to placebo
*HR 0.53 [95% CI 0.35-0.82], p=0.0038
33.7%
of patients receiving olaparib
remained progression-free
after one year
68% data maturity
Tumor
agnostic
HRRm Basket (LYNK-002)
0.9-
0.8-
0.6-
05-
Olaparib (N=92: 60 events)
02-
0.1-
0.0-
Placebo
(N-62; 44 events)
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50
Months since randomization
No. at Risk
Olaparib 92 69 50 41 34 24 18 17 14 10 10 8 8 7 5 3 3 3 3 2 11 10
Placebo 62 39 23 10 6 6 4 4 4 2 2 2 2 1 1 0
Demonstrating potential in prostate cancer, pancreatic cancer and more
Collaboration with AstraZeneca
PRR: Platinum Relapsed Recurrent; PSR: Platinum Sensitive Recurrent
MERCK
H
Dr. Roy Baynes
INVENTING FOR LIFE
56View entire presentation